Severe shortage? 1,500 inspectors too few for India's 10,000 plants says ASSOCHAM

By Gareth Macdonald contact

- Last updated on GMT

Severe shortage? 1,500 inspectors too few for India's 10,000 plants says ASSOCHAM

Related tags: Regulation, India

New Delhi industry group ASSOCHAM says international criticism of Indian drug and API plants is due to a ‘severe shortage’ of regulatory inspectors.

The Associated Chambers of Commerce & Industry of India (ASSOCHAM) claimed​ today that the various national and regional agencies that oversee drug and API production in the country employ "only" 1,500 inspectors.

ASSOCHAM contrasted this with India’s estimated 10,000 manufacturing facilities and suggested this "mismatch", combined with differences between regulations in India and international markets – primarily the US - is hurting exporters.

General Secretary D.S. Rawat said: “While at times, the US FDA gets into minute details which have more to do with the cumbersome procedure rather than quality, we need to get our own house in order by way of continuous skilling of the regulators at the national and state levels in sync with the best global practices​.”

Too few inspectors?

Whether there are too few inspectors in India is a matter of debate with one Europe-based facility assessor we asked suggesting that 1,500 staff should be enough.

Typically an inspection should last about 3 – 5 man-days or 1.5 – 2.5 days with two persons" ​he said, adding that "even if you consider that authority inspections are often longer – taking between 4 and 8 man-days, or 2 to 4 days with two inspectors, this should be o​k.”

Facility assessments in India take between two and five days, according to a Central Drugs Standard Control Organisation (CDSCO​) document with inspectors then having a week to submit reports for review by Zonal and State licensing authorities.

This nine to 13 day schedule allocates roughly the same amount of time for site visits as the US FDA which, last year, was 35.4 hours​.

Multiple Agencies

One factor that supports ASSOCHAM’s shortage claim is the fact that inspectors work for multiple national and regional bodies – the Central Regulatory Agency, CDSCO and State FDAs to name a few – which do not always collaborate very effectively according to the industry group.

The pharmaceutical industry in India has a concurrent regulatory practice, which is sometimes poorly manned and poorly headed by less knowledgeable pharmacists who are not properly trained. Lower awareness among such personnel regarding the quality norms leads to non-uniform implementation of regulatory standards.

ASSOCHAM also called for greater international collaboration between regulators.

Mr Rawat said: “With the absence of global harmonization of quality systems makes it all the more challenging for India that exports to US, Europe, Australia, Japan, to comply with a plethora of regulatory guidelines across the globe​.”

Related news

Show more

Related products

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars